Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022
Amgen has proven that it can manage market downturns fairly well. The company is also an excellent dividend stock.
AMGN - Amgen Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$393.72
DETAILS
HIGH:
$460.00
LOW:
$230.00
MEDIAN:
$394.50
CONSENSUS:
$393.72
UPSIDE:
3.67%
Stock News
September Syndrome in Full Swing: 3 Picks to Safeguard Your Portfolio
September's market jitters highlight defensive stocks, ADM, AMGN and SUN, with low betas, high yields, raising 2026 guidance and improving earnings estimates.
Amgen Highlights MariTide, IMDELLTRA Pipeline Progress and Growth Priorities
Amgen NASDAQ: AMGN outlined its growth priorities, late-stage pipeline progress and capital-allocation framework during a Morgan Stanley conference, as newly appointed Chief Financial Officer Thomas Dittrich emphasized execution, financial discipline and cash-on-cash returns.
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits?
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.
Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
4 Defensive Stocks to Take Refuge in as Consumer Sentiment Plummets
ADM, COCO, AMGN and CNC offer defensive exposure as inflation, oil prices and weak consumer sentiment fuel market volatility.
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.
Here's Why Amgen (AMGN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike
AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.
FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
Update Supports Broader Access to IMDELLTRA in Community Settings for People Living with Extensive-Stage Small Cell Lung Cancer THOUSAND OAKS, Calif., Sept. 14, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved an update to the IMDELLTRA® (tarlatamab-dlle) Prescribing Information that substantially reduces the recommended monitoring time for the first two doses of treatment in an appropriate healthcare setting.
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Amgen maintains a massive, diversified portfolio of medicines serving approximately 17 million patients globally. Vertex Pharmaceuticals dominates the cystic fibrosis market with exceptionally high net margins and a pristine balance sheet.
Amgen Highlights 26% Growth Drivers, IMDELLTRA Momentum and MariTide Potential
Amgen NASDAQ: AMGN executives highlighted growth across its key commercial products, progress in late-stage development programs and a continued focus on profitability and cash returns during a Wells Fargo biotech and pharma discussion.
Amgen Drops 10% on a Trial It Didn't Even Run
Amgen TodayAMGNAmgen$379.72 -2.75 (-0.72%) As of 12:05 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$269.77▼$447.03Dividend Yield2.65%P/E Ratio23.61Price Target$381.68Add to WatchlistAmgen Inc. NASDAQ: AMGN delivered a strong earnings report on Aug. 4.
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Amgen maintains a massive global footprint and generated over $8.1 billion in free cash flow during its latest fiscal year. Revolution Medicines is a clinical-stage oncology specialist focused on high-stakes breakthrough therapies for RAS-addicted cancers.
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Amgen provides a stable foundation with multi-billion dollar revenues and consistent cash flows. CRISPR Therapeutics offers high growth potential through its pioneering gene-editing technology.
Are Medical Stocks Lagging Amgen (AMGN) This Year?
Here is how Amgen (AMGN) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
Amgen (AMGN) Dips More Than Broader Market: What You Should Know
The latest trading day saw Amgen (AMGN) settling at $382.47, representing a -2.25% change from its previous close.
Amgen Inc. (AMGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Amgen Inc. (AMGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, potentially broadening both drugs' reach.
Price Targets
Amgen (AMGN) PT Lowered to $430 at UBS
$430.00
(was $378.42)
Michael Yee
·
UBS
Amgen (AMGN) PT Raised to $435 at Wells Fargo
$435.00
(was $444.12)
Mohit Bansal
·
Wells Fargo
Amgen price target raised to $457 from $427 at Piper Sandler
$457.00
(was $442.36)
David Amsellem
·
Piper Sandler
Amgen price target raised to $362 from $351 at Morgan Stanley
$362.00
(was $440.28)
Morgan Stanley
Amgen price target raised to $460 from $375 at Argus
$460.00
(was $439.95)
Argus Research
Amgen price target raised to $400 from $350 at Cantor Fitzgerald
$400.00
(was $419.38)
Cantor Fitzgerald
Amgen price target raised to $352 from $303 at Mizuho
$352.00
(was $419.38)
Mizuho Securities
Amgen price target raised to $380 from $360 at Barclays
$380.00
(was $417.84)
Emily Field
·
Barclays
Amgen (AMGN) PT Raised to $388 at Guggenheim
$388.00
(was $410.94)
Vamil Divan
·
Guggenheim
Amgen price target raised to $345 from $335 at Bernstein
$345.00
(was $407.83)
Bernstein
Amgen price target raised to $450 from $385 at Scotiabank
$450.00
(was $406.25)
Louise Chen
·
Scotiabank
Amgen price target raised to $450 from $400 at Oppenheimer
$450.00
(was $390.02)
Oppenheimer
Amgen price target raised to $400 from $370 at RBC Capital
$400.00
(was $390.02)
RBC Capital
Amgen price target raised to $230 from $215 at Baird
$230.00
(was $390.02)
Brian Skorney
·
Robert W. Baird
Amgen price target raised to $384 from $366 at Canaccord
$384.00
(was $390.02)
Gary Nachman
·
Canaccord Genuity
Amgen price target raised to $450 from $400 at BMO Capital
$450.00
(was $390.02)
Evan Seigerman
·
BMO Capital
Amgen price target raised to $360 from $350 at Barclays
$360.00
(was $393.10)
Emily Field
·
Barclays
Amgen price target raised to $420 from $400 at UBS
$420.00
(was $358.68)
UBS
Amgen (AMGN) PT Raised to $343 at GuggenheimMember Login
$343.00
(was $363.39)
Guggenheim
Amgen price target lowered to $333 from $340 at Morgan Stanley
$333.00
(was $368.10)
Morgan Stanley